Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports. (2nd July 2020)

• Record Type: Journal Article
• Authors: Nagayasu, Atsushi; Nawata, Masao; Saito, Kazuyoshi; Tanaka, Yoshiya
• Is Part Of: Modern rheumatology case reports. Volume 4:Number 2(2020)
• Page Start: 176
• Page End: 180
• Publication Date: 2020-07-02
• Subjects: Psoriatic arthritis -- spondyloarthritis -- Ixekizumab -- IL-17 inhibitor -- magnetic resonance imaging; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/24725625.2019.1703546
• Languages: English
• ISSNs: 2472-5625

Abstract

Abstract: Psoriatic arthritis (PsA) manifests not only skin lesion but also peripheral and axial joint involvements, thus the disease is considered to be part of spondyloarthritis. In patients with active spondyloarthritis, tumour necrosis factor inhibitors biologics are often considered, but there is not sufficient evidence about other type of biologics. Ixekizumab (IXE) is a humanised monoclonal antibody, which acts against interleukin-17A, a cytokine involved in psoriasis pathogenesis. IXE was administered to two patients with refractory PsA, manifested via extended skin lesions and complicated by axial joint involvement. The effectiveness and imaging results during 12 weeks of treatment were assessed. IXE improved disease activity in both a tumour necrosis factor inhibitors biologics-inadequate responder and a bio-naïve patient and, consequently, IXE probably plays a key role in treatment of axial disease of PsA.